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ABSTRACT 
 
 The liver parenchyma is populated by hepatocytes and several 
non-parenchymal cell types including Kupffer cells and hepatic stellate cells. 
Both Kupffer cells and hepatic stellate cells are responsive to the chemokine 
CCL2, but the precise roles of CCL2 and these cells in liver tumor formation 
remain undefined. Hence, we investigated the effects of the lack of the major 
CCL2 receptor, CCR2, on liver tumor formation induced by intraportal injection 
of the murine colon adenocarcinoma cell line, colon 26. Wild-type mice showed 
macroscopic tumor foci in the liver 10 days after injection of colon 26 cells. 
After 10 days, CCL2 proteins were detected predominantly in tumor cells, 
coincident with increased intratumoral macrophage and hepatic stellate cell 
numbers. Although tumor formation occurred at similar rates in wild-type and 
CCR2-deficient mice up to 10 days after tumor cell injection, the number and size 
of tumor foci were significantly attenuated in CCR2-deficient mice relative to 
wild-type mice thereafter. Moreover, neovascularization and matrix 
metalloproteinase 2 expression were diminished in CCR2-deficient mice with a 
concomitant reduction in the accumulation of macrophages and hepatic stellate 
cells. Furthermore, matrix metalloproteinase 2 was detected predominantly in 
hepatic stellate cells but not in macrophages. We provided the first definitive 
evidence that the absence of CCR2-mediated signals can reduce the trafficking of 
hepatic stellate cells, a main source of matrix metalloproteinase 2, and 
consequently can diminish neovascularization during liver tumor formation. 
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INTRODUCTION 
 
 Liver metastasis is a common complication among patients with tumors of 
the gastrointestinal tract, especially colon,1 and it is one of the major factors 
influencing the prognosis of these patients. A better understanding of the liver 
metastatic process at both the cellular and molecular levels is required to develop 
novel therapeutic strategies. Accumulating evidence suggests that metastasis 
proceeds by the interaction between tumor cells and resident cells in various 
target organs. However, the role of resident cells in the liver during liver 
metastasis remains to be investigated fully. 
 The liver consists of hepatic parenchymal cells and a variety of 
non-parenchymal cell types, including Kupffer cells (KC), hepatic stellate cells 
(HSC), endothelial cells (EC), and several sets of resident lymphocytes. KC 
belong to the macrophage lineage and are presumed to have crucial roles in the 
first-line defense in liver to eradicate microorganisms and eliminate toxic 
substances.2,3  KC have also exhibited direct cytotoxic activity against tumor cell 
lines in vitro.4 In in vivo models of liver metastasis, tumor cells tended to adhere 
to the sinusoid endothelium and were phagocytosed by KC that were attracted to 
these sites.5,6 In contrast to these findings, a role for KC in promoting liver 
metastasis has also been proposed. In human colorectal cancer liver metastasis, 
the density of KC correlated well with microvessel density and inversely with 
prognosis.7 Moreover, the demonstrated ability of carcinoembyronic antigen 
(CEA) to promote metastasis to liver in some experimental tumor models may be 
mediated by KC.8,9 Support for this idea comes from the finding that KC treated 
with CEA and related molecules in vitro produce several pro-inflammatory 
cytokines such as IL-1, IL-6, and TNF-α. These molecules induce the expression 
of adhesion molecules on endothelial cells, which would serve to promote the 
metastatic process.10,11 Thus, the role of KC in liver metastasis needs to be 
                                                            Yang 4 
clarified. 
 Several recent reports have presented evidence to support the idea that 
HSC also contribute to liver metastasis.  Melanoma cells induce HSC to secrete 
matrix metalloproteinase (MMP) 2 during experimental liver metastasis.12 
Moreover, intrasplenic injection of murine melanoma cells induced the 
accumulation in the liver of activated HSC, and vascular endothelial growth 
factor (VEGF) produced by these cells facilitated neovascularization.13 However, 
it remains to be determined which factor(s) regulates the trafficking of HSC. 
 CCL2/monocyte chemoattractant protein (MCP)-1, a member of the CC 
chemokine family, induces a wide variety of functional activities in 
monocytes/macrophages, including chemotaxis, the release of reactive oxygen 
species and lysosomal enzymes, and enhancement of their tumoricidal 
activities.14 CCR2 is the major, if not only, receptor for CCL2,15,16 and it is 
expressed by various types of macrophage lineage cells, including KC,17 and by 
tumor-infiltrating macrophages in various human18,19 and murine tumors.20 
Moreover, CCL2 is produced by a variety of cancer cell types,21 suggesting that 
CCL2 is involved in the local accumulation of tumor-associated macrophage 
lineage cells. The fact that CCL2 is also chemotactic for HSC suggests that it 
may play a significant role in metastasis of the liver by recruiting HSC.22 In this 
report, we used CCR2-deficient mice in a model of liver metastasis to investigate 
whether the CCL2-CCR2 axis is involved in macrophage and HSC accumulation 
in the liver and whether there is an effect on subsequent tumor development and 
neovascularization. 
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MATERIAL AND METHODS 
 
Antibodies  Rat anti-mouse F4/80 (clone A3-1) and anti-mouse CD34 (clone 
MEC14.7) monoclonal antibodies were obtained from Serotec (Oxford, United 
Kingdom). Rabbit anti-mouse CCL2 IgG was prepared as described previously.20 
Goat anti-mouse CCR2 antibody was obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Mouse anti-human α smooth muscle actin (αSMA; clone 1A4) 
monoclonal antibody, which can detect also the mouse antigen, was obtained 
from DAKO (Denmark). Goat anti-mouse MMP2 antibody was obtained from 
R&D Systems (Minneapolis, MN). Rat anti-mouse ER-MP20 monoclonal 
antibody was purchased from Biomedicals (Augst, Switzerland). Isotype-matched 
IgG from the same species was used as negative control. 
 
Mice  Specific pathogen-free 8 to 10-week old female BALB/c mice were 
purchased from Charles River Japan CO. (Yokohama, Japan) and designated as 
WT mice. CCR2-deficient mice were generated as described previously,23 
backcrossed to BALB/c mice for more than 8 generations in our animal facility 
and designated as CCR2 KO mice. CCR2 mRNA was detected in splenocytes and 
peritoneal macrophages obtained from WT but not CCR2 KO mice (our 
unpublished data), confirming the lack of CCR2 gene expression in CCR2 KO 
mice. All the animal experiments were performed under specific pathogen-free 
conditions in accordance with the Guideline for the Care and Use of Laboratory 
Animals in Takara-machi Campus of Kanazawa University. 
 
Induction of liver tumor formation  A murine colon adenocarcinoma cell line, 
colon 26,20,24 was maintained in RPMI1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum at 37°C in a humidified atmosphere with 5% 
CO2. Subconfluent cells were harvested, washed twice with Hank’s balance salt 
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solution (HBSS) and resuspended in HBSS at a density of 1.25 × 105 cells/ml. 
The cell viability was always more than 95% by a trypan blue exclusion test. 
Mice were anesthetized with an intraperitoneal injection of 1.8% (v/v) Avertin at 
a dose of 0.15 ml/10 g body weight.25 Then, mice underwent laparotomy by an 
upper median incision to expose the duodenal loop and 200 μl of a suspension of 
colon 26 cells was injected into the portal vein using a 30-guage needle attached 
to a 1 ml syringe. To prevent bleeding and peritoneal dissemination of tumor cells, 
a sterile cotton sponge was placed over the injection site.26 Mice were sacrificed 
at the indicated time intervals after tumor injection to determine the body weight, 
liver weight, incidence of liver tumor formation, and the number of tumor foci in 
liver tissue. In another series of experiments, the livers were obtained for 
histological analysis and total RNA extraction. 
 
Histological analysis  A portion of liver tissue was fixed with 10% formalin 
neutral buffer solution and embedded in paraffin. The sections were cut at the 
thickness of 5 μm and stained with a hematoxylin and eosin solution. The 
numbers and sizes of the tumor foci were determined according to the method 
described by Pierce27 by using a digital camera mounted on a microscope. The 
images were imported into Adobe Photoshop ver 7.0 (Adobe Systems Inc., San 
Jose, CA), and the foci number per cm2 and the proportions of areas occupied 
with tumor foci were determined with the use of NIH Image Analysis Software 
ver 1.62 (National Institutes of Health, Bethesda, MD) 
 
Immunohistochemical analysis  Paraffin-embedded sections were deparaffinized 
and incubated for 30 min with 1% H2O2 in methanol to eliminate endogenous 
peroxidase. Then, for antigen retrieval, sections were treated with 0.1% trypsin in 
0.1% CaCl2 for 15 min at 37°C, or immersed in 10 mM sodium citrate buffer (pH 
6.0) and heated for 20 min in a microwave oven. Subsequently, endogenous 
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avidin and biotin were blocked with Avidin-Biotin Blocking kit (Vector 
Laboratories, Burlingame, CA), and nonspecific protein binding was blocked 
with 10% serum obtained from the same species used to produce the secondary 
antibody. Thereafter, the sections were incubated with rat anti-mouse F4/80 (1 
μg/ml), anti-CD34 (5 μg/ml), anti-ER-MP20 (5 μg/ml), rabbit anti-CCL2 (10 
μg/ml), goat anti-CCR2 (2 μg/ml) or anti-MMP2 (5 μg/ml), overnight at 4°C. 
After being washed, the sections were incubated for 45 min at room temperature 
with biotinylated anti-rat Ig, anti-rabbit Ig, and anti-goat Ig antibodies to detect 
CD34, ER-MP20, CCL2, CCR2, and MMP2, respectively. The immune complexes 
were visualized using ELITE ABC kit (Vector Laboratories) according to the 
manufacturers’ instruction. No positive reactions were observed under the present 
condition when isotype-matched control Ig was used instead of specific primary 
antibodies. The number of CCL2-positive cells inside tumor foci, was determined 
in each animal on five randomly chosen fields at 400-fold magnification. To 
detect F4/80 antigen, Catalyzed Signal Amplification System (DAKO, 
Carpinteria, CA) was used according to the manufacturers’ instruction.  After 
F4/80-positive cells were counted on five randomly chosen fields in each animal 
at 200-fold magnification by an examiner without any prior knowledge of the 
experimental procedures, their numbers were calculated for tumor and non-tumor 
areas. For an immunohistochemical staining of activated HSC, DAKO Envision 
System (DAKO, Carpinteria, CA) was used together with mouse anti-αSMA as 
previously described.28 The pixel numbers of αSMA-positive areas were 
determined and HSC density was expressed as percentage of the whole metastasis 
area as previously described.28
 
Intratumoral microvessel density (IMVD)  CD34-positive areas in the tumor 
tissues were defined as the intratumoral vascular areas.29 Areas of abundant 
neovascularization (hot spots) were found inside metastasis foci by scanning the 
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sections at low magnification, and then the pixel numbers of CD34-positive areas 
were determined on five randomly chosen fields in hot spots of each animal at 
200-fold magnification with the aid of Adobe Photoshop software Ver 7.0. The 
density of neovascularization was expressed as percentage of the whole 
metastasis area. 
 
Double-color immunofluorescence analysis  Sections were deparaffinized, and 
treated with 0.1% trypsin for 15 min at 37°C for antigen retrieval. Thereafter, 
sections were incubated with the combination of rat anti-mouse F4/80 and goat 
anti-mouse MMP2, anti-αSMA and anti-MMP2, goat anti-mouse CCR2 and 
anti-F4/80, or anti-CCR2 and anti-αSMA antibodies overnight at 4°C. After 
being rinsed with PBS, for a double immunofluorescence analysis using 
anti-F4/80, the sections were incubated with FITC-conjugated donkey anti-rat 
IgG (1/50) and Cy3-conjugated donkey anti-goat IgG (1/100) (Molecular Probes, 
Inc., Eugene, OR) for 30 min at room temperature in dark. For a double 
immunofluorescence analysis using anti-αSMA, the sections were first incubated 
with biotinylated anti-mouse Ig (1/100) for 45 min at room temperature, and 
subsequently with FITC-conjugated streptavidin (1/50) and Cy3-conjugated 
donkey anti-goat IgG (1/100) for 30 min at room temperature in dark. Finally, 
sections were washed with PBS and immunofluorescence was visualized in a dual 
channel mode on a fluorescence microscope (Olympus, Tokyo, Japan). Images 
were processed using Adobe Photoshop software Ver 7.0. 
 
RNA Isolation and semi-quantitative RT-PCR  Total RNA was extracted from a 
fragment of liver tissue with RNA-BeeTM (Tel-Test, Inc., Friends Woods, TX) 
according to the manufacturers’ instruction. The RNA preparations were then 
treated with ribonuclease-free deoxyribonuclease (DNase) I (Life Technologies, 
Inc., Gaithersburg, MD) to remove residual genomic DNA. Two µg of total RNA 
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was reverse-transcribed at 42°C for 1 hr in 20 µl of reaction mixture containing 
mouse Moloney leukemia virus reverse transcriptase (Toyobo, Osaka, Japan) and 
hexanucleotide random primers (Amersham Biosciences, Tokyo, Japan). Serially 
two-fold diluted cDNA products were amplified for β-actin using specific set of 
primers (Table I) with 25 cycles of 94°C for 30 sec, 55°C for 1 min, and 72°C for 
1 min, in 25 µl of reaction mixture containing Taq polymerase (Takara Shuzo, 
Kyoto, Japan) to evaluate the amount of the transcribed cDNA. Thereafter, equal 
amounts of cDNA products were amplified for the indicated genes using specific 
sets of primers based on the reported sequences, with the optimal cycle numbers 
of 94ºC for 30 sec, 55°C for 1 min, and 72°C for 1 min (Table I). After the 
amplification, the resultant PCR products were fractionated on a 1.2% agarose 
gel and visualized by ethidium bromide staining under ultraviolet light 
transillumination. The intensities of the bands were determined using NIH Image 
Analysis Software Ver 1.62 and the ratios to β-actin were determined.28,30  
 
CCL2 enzyme-linked immunosorbent assay (ELISA)  Liver tissues were obtained 
at the indicated time points and were homogenized in 10 volumes [1:10 (wt:vol)] 
of RIPA buffer [50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% 
polyoyehylene (9) octylphenyl ether, and 2 mM phenylmethane sulfonyl fluoride] 
on ice. The homogenates were then centrifuged at 10,000 × g for 10 min at 4°C, 
and the resulting supernatants were transferred to a fresh tube and stored at -80°C 
until use. Total protein concentrations were determined using Bio-Rad protein 
assay kit (Bio-Rad Laboratories, Hercules, CA), using bovine serum albumin as a 
standard. Then, CCL2 contents in the supernatants were determined with the 
mouse CCL2 ELISA kit (BioSource Inc., Camerillo, CA) according to the 
manufacturers’ instruction. The data were expressed as CCL2 (pg)/total protein 
(mg) for each sample. 
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HSC isolation and culture  HSC were isolated from WT mouse livers by 
perfusing the liver tissues with a combination of Pronase E (Merck, Damstadt, 
Germany) and Collagenase type IV (Sigma, St. Louis, MO) solution, followed by 
Nycodenz○R  (ICN Biomedicals Inc., Aurora, Ohio) gradient centrifugation as 
described previously.31 HSC were harvested from the top density gradient layer 
of 1.025-1.035 g/ml. The isolated cell population exhibited a rapidly fading 
blue-green autofluorescence at 328 nm excitation wavelength, a characteristic 
feature of HSC.31 HSC were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal calf serum (FCS) and 10% horse serum, penicillin 
(100 U/mL), and streptomycin (100 μg/mL). Culture medium was changed after 
overnight culture and then changed every two days. After 5 days of culture on 
uncoated plastic, all the HSC exhibited the phenotype of well spread 
myofibroblast-like cells with specific αSMA expression. The viability and purity 
of HSC were more than 95 and 98% as assessed by trypan blue exclusion and the 
presence of rapidly fading autofluorescence, respectively. Total RNA was 
extracted from the resultant HSC population for RT-PCR analysis. 
 
Statistical analysis  Data were analyzed statistically using one-way ANOVA 
followed by the Fisher’s protected least significance difference test or 
Mann-Whitney’s test. p<0.05 was considered statistically significant. 
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RESULTS 
 
Liver metastasis formation  Microscopic metastases appeared in the liver of WT 
mice at 6 days after the intraportal injection of colon 26 cells (data not shown). 
At 10 days after the injection of the tumor cells, macroscopic metastasis foci 
were evident and both the number and size of the foci progressively increased 
thereafter in WT mice (Table II). 
 
Expression of CCR2 and its ligands during liver metastasis formation  Because 
colon 26 cells constitutively express mRNA for CCR2 ligands (our unpublished 
data), we used RT-PCR to monitor changes in the RNA levels of CCR2 ligands 
during the course of liver metastasis. This analysis on the livers of untreated WT 
mice showed barely detectable expression of the genes for CCL2/MCP-1, 
CCL7/MCP-3 and CCL12/MCP-5 as well as for CCR2 (Fig. 1a, b). However, 
intraportal injection of colon 26 cells in WT mice dramatically increased the 
levels of RNA for CCL2, CCL7, and CCL12 when measured at both 10 and 14 
days after the injection (Fig. 1a, b). CCR2 RNA levels also rose during this time 
period but to a lesser extent than RNA for the CCR2 ligands in WT mice (Fig. 1a, 
b). We next examined whether the increase in CCL2 RNA correlated with an 
increase in CCL2 protein during the course of liver metastasis in this model. By 
immunohistochemical analysis, CCL2 was barely detectable in the liver of 
untreated WT mice and until 6 days after the tumor injection (data not shown). 
However, ten days after the injection of tumor cells, the time when macroscopic 
metastasis foci first appeared, CCL2 was abundantly detected in the tumor cells 
(Fig. 1C-i) but to a lesser degree in the tumor vasculature (Fig. 1c-ii) and bile 
duct epithelia (Fig. 1c-iii).  The number of CCL2-positive cells increased 
further at 14 days after injection of tumor cells (Fig. 1c-iv, d). Consistent with 
RT-PCR analysis and immunohistochemical analysis, intrahepatic CCL2 contents 
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were increased dramatically from 10 days after the injection in WT mice (Fig. 1e). 
CCR2-positive cells were detected predominantly inside tumor foci (Fig. 1c-v) 
and to a lesser extent in the sinusoids of tumor-free areas of the liver of WT mice 
(Fig. 1c-vi). 
 
Reduced liver tumor formation in CCR2 KO Mice  To clarify the pathological 
roles of CCR2-mediated signals in this liver metastasis model, we injected the 
same number of colon 26 cells into the portal veins of WT and CCR2 KO mice. 
Ten days after the injection of tumor cells, there were no significant differences 
between these two mouse strains in terms of liver weights, liver-to-body weight 
ratios, and number of metastasis foci in the liver tissue (Table II). At 14 days, 
however, liver weights and liver-to-body weight ratios of WT mice were nearly 
twice those of CCR2 KO mice. Moreover, the number of tumor foci per cm2 and 
the liver area occupied by tumor foci were increased nearly four times in WT 
mice relative to CCR2 KO mice (Table II).  Furthermore, 6 out of 16 CCR2 KO 
mice survived at 22 days after the tumor injection, when all WT mice died due to 
heavy tumor burden. The median survival time was prolonged marginally in 
CCR2 KO, compared with WT mice (WT, 17.4 days; CCR2 KO, 20.9 days. 
p<0.05). On the contrary, there were no significant differences in CCR2 ligand 
mRNA expression between WT and CCR2 KO mice (Fig. 1a, b). Moreover, the 
number of CCL2-positive cells in the tumor sites as well as intrahepatic CCL2 
contents were increased in WT and CCR2 KO mice to a similar extent (Fig. 1d, e).  
As expected, no CCR2-positive cells were detected in the tumor sites of CCR2 
KO mice (data not shown). These observations suggest that the absence of CCR2 
did not result in compensatory enhancement of the expression of its ligands. 
 
Reduced accumulation of macrophages and HSC in CCR2 KO mice  
Macrophages and HSC have been reported to respond to CCL2 in chemotaxis 
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assays.22 Therefore, we examined macrophage and HSC accumulation in liver 
tumor foci in WT and CCR2 KO mice by F4/80 and αSMA staining, respectively. 
At 10 days after tumor cell injection, there were no significant differences in 
macrophage numbers in tumor and non-tumor areas of the liver between WT and 
CCR2 KO mice. However, at 14 days after tumor cell injection, WT mice but not 
CCR2 KO mice showed a significant increase in macrophage number in tumor 
areas of the liver (Fig. 2). Similar results were obtained on the number of 
αSMA-positive activated HSC in liver tumor foci (Fig. 3). Because F4/80 can 
recognize both resident sinusoidal macrophages/KC and blood-derived 
macrophages in the liver, we next used ER-MP20,32 to identify the blood-derived 
macrophages. Among F4/80-positive macrophages, 1.78% and 2.07% were also 
positive for ER-MP20, in liver of untreated WT and CCR2 KO mice, respectively. 
At 14 days after the tumor injection, 20.13 ± 4.78% and 22.57 ± 3.46% of 
F4/80-positive cells in the tumor areas were also positive for ER-MP20 in WT 
and CCR2 KO mice (n = 6), respectively. Collectively, these results suggest that 
both F4/80+ER-MP20- resident sinusoidal macrophages/KC and F4/80+ER-MP20+ 
blood-derived macrophages accumulated in the tumor areas in addition to HSC 
and that CCR2-mediated signals were involved in the trafficking of these cells to 
a similar extent. 
 
Reduced neovascularization and MMP2 expression in liver tumor foci in CCR2 
KO mice  Tumor formation was delayed in CCR2 KO mice 14 days after tumor 
injection. Because neovascularization is a prerequisite for metastasis, 
particularly in the growth of metastasis foci,33 we evaluated angiogenesis in the 
livers by immunohistochemistry with antibodies that recognize CD34, a marker 
of endothelial cells.29 In WT mice, neovascularization became evident by 10 days 
after tumor cell injection and the neovascular areas increased thereafter (Fig. 4). 
In sharp contrast, microvessel densities inside metastasis foci in CCR2 KO mice 
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did not increase from 10 to 14 days after the injection of tumor cells (Fig. 4). We 
next used RT-PCR to monitor changes in expression of genes for MMPs and 
cytokines that exhibit pro-angiogenic activities in order to evaluate the potential 
contribution of these factors to neovascularization in liver metastasis. Among 
these angiogenic factors, there was no change in the level of RT-PCR products for 
vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and 
the VEGF receptors flt-1 (FMS-like tyrosine kinase 1/VEGF receptor 2) and flk-1 
(fetal liver kinase, protein-tyrosine kinase receptor/VEGF receptor 1) during the 
course of metastasis (Fig. 5). In contrast, the level of basic fibroblast growth 
factor (bFGF) RNA was increased in WT mice beginning at the day 10 and day 14 
time points. Placenta-derived growth factor (PlGF) RNA was first detectable only 
at day 10 and the RNA levels increased further at day 14. The enhanced gene 
expression tended to be less evident in CCR2 KO mice although the differences 
did not reach statistical significance (Fig. 5). Among MMPs, mRNA for MMP2, 
MMP9 and MMP13 was enhanced in the liver of WT mice at 10 days after tumor 
cell injection. TIMP-1 RNA was first detectable at this time point (Fig. 5). The 
only significant difference between WT and CCR2 KO mice was the reduction in 
MMP2 RNA in the latter strain at 14 days (Fig. 5). 
 
MMP2 expression in HSC  Several lines of evidence suggest that MMP2 is 
expressed by αSMA-positive cells but not by KC in human primary 
hepatocellular carcinoma and in liver metastasis.34,35 Consistent with this notion, 
a double-color immunofluorescence analysis failed to detect immunoreactive 
MMP2 in F4/80+ cells inside tumor areas (Fig. 6a). In untreated WT mouse liver, 
MMP2 protein was barely detected (data not shown). In contrast, a double-color 
immunofluorescence analysis confirmed that MMP2 protein is associated with 
αSMA-positive cells in the tumor sites derived from WT (Fig. 6b, upper panel). A 
quantitative analysis further demonstrated that 65.6 ± 13.7% of MMP2-positive 
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areas were also positive for αSMA in WT mice  Moreover, MMP2 protein was 
detected in αSMA-positive cells in the tumor sites derived from CCR2 KO mice 
(Fig. 6b, lower panel). Considering the sensitivities of a double-color 
immunofluorescence analysis, these results show that HSC but not F4/80-positive 
macrophage linage cells are the main source of MMP2, a potent inducer of 
angiogenesis. 
 
CCR2 expression on macrophage and HSC  Since the absence of CCR2 protein 
on HSC was reported previously,22 we examined CCR2 expression on 
αSMA-positive and on F4/80-positive cells by a double-color 
immunofluorescence analysis. CCR2 protein was detected on most F4/80-positive 
cells (Fig. 7a) but not on αSMA-positive cells (Fig. 7b). We next isolated HSC 
from untreated WT mice and extracted total RNA for RT-PCR analysis. RT-PCR 
analysis detected specific CCR2 transcript in HSC population (Fig. 7c). Because 
an immunofluorescence analysis cannot detect a modest number of surface 
antigen, these observations suggest that HSC expressed a small number of CCR2, 
which can be detected only by a sensitive RT-PCR but not an 
immunofluorescence analysis. Thus, it is likely that CCR2 has direct effects for 
HSC, although we cannot completely exclude the possibility that CCR2-mediated 
F4/80-positve macrophage accumulation and activation may indirectly activate 
HSC as reported previously.36
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DISCCUSSION 
 
Tumor formation was delayed in CCR2 KO mice only after macroscopic 
foci appeared in this model. These observations prompted us to evaluate 
neovascularization, a crucially responsible process for growth of tumor foci.33  
CD34-positive vascular areas were diminished in CCR2 KO mice, compared with 
WT mice. Thus, reduced neovascularization may account for delayed tumor 
formation in CCR2 KO mice. 
Neovascularization consists of multiple steps that include the degradation 
of basement membrane surrounding an existing vessel, migration and 
proliferation of endothelial and mural cells, and lumen formation.33 These 
processes are regulated by MMPs37 and angiogenic factors such as VEGF, bFGF, 
PlGF, and HGF.38-41 CCR2 KO mice exhibited reduced neovascularization 
concomitantly with reduced accumulation of hepatic macrophages and hepatic 
stellate cells. Because macrophages are known to be a main source of these 
factors,42-44 it was not surprising that we found increased levels of RNA for PlGF, 
bFGF, MMP2, MMP9 and MMP13 in the liver after intraportal injection of tumor 
cells. Although the expression of all these genes tended to be decreased in CCR2 
KO mice, only the level of MMP2 RNA was significantly attenuated in these 
animals compared with WT mice. MMP2 can induce tube formation by 
endothelial cells45 by binding with integrin αvβ3 on these cells.46 The crucial 
involvement of MMP2 in tumor neovascularization is supported by the 
observation of reduced tumor neovascularization and tumor formation in 
MMP2-deficient mice.47 Thus, reduced MMP2 expression might account for the 
diminished neovascularization and subsequent retarded liver tumor formation in 
CCR2 KO mice, although the contribution of PlGF, bFGF, and other MMPs 
cannot be completely excluded. 
 Previous in situ hybridization analysis revealed that activated HSC 
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express the MMP2 gene in human primary hepatocellular carcinoma and liver 
metastasis.34,35 Moreover, HSC can secrete MMP2 upon interaction with 
melanoma cells in vitro.12 Consistently, we have shown by immunohistological 
analysis that HSC but not macrophages are a primary source of MMP2 in this 
model. HSC infiltrated tumor foci in a time-dependent manner in WT mice and 
HSC accumulation was significantly reduced in CCR2 KO mice, compared with 
WT mice. The absence of CCR2-mediated signals lessened the intratumoral 
accumulation of HSC, a rich source of MMP2, thereby reducing angiogenesis, a 
prerequisite step for the latter phase of metastasis focus growth. This may explain 
why the absence of CCR2 attenuated tumor formation only at 14 days after the 
tumor injection, the relatively later phase of tumor progression. This notion can 
be corroborated by the previous observation that HSC appeared in avascular 
micrometastasis foci preceding endothelial cell recruitment in mouse liver 
metastasis arising from intrasplenic injection of B16 melanoma cells.13
 We previously observed that CCL2 gene transfer enhanced the capacity of 
colon 26 cells to metastasize to lungs with a concomitant increase in 
neovascularization at the metastasis sites without any augmentation in 
macrophage infiltration.48 These observations suggest that CCL2 might possess 
direct angiogenic activities, a notion that is supported by the expression of CCR2 
by human endothelial cells.49,50 Moreover, CCR2 was expressed by intratumoral 
F4/80-positive macrophages, which can secrete various angiogenc factors and 
MMP, including bFGF and MMP942-44,51. CCR2 deficiency resulted in the 
reduction in bFGF and MMP9 gene expression marginally but not significantly 
with a concomitant apparent reduction in macrophage infiltration. Thus, in this 
model, CCR2-mediated signals induced the accumulation of macrophages, which 
can contribute to neovascularization by secreting these factors, in concert with 
MMP2 expressed mainly by HSC. 
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 LEGENDS TO FIGURES 
 
Figure 1－ Expression of CCR2 and its ligands in the liver.  (a) RT-PCR 
analysis was performed on total RNA extracted from the livers of WT or CCR2 
KO mice at the indicated time intervals after tumor cell injection as described in 
Material and Methods. RT-PCR analyses were performed, and representative 
results from 6 individual experiments are shown here.  (b) The ratios of 
chemokines and chemokine receptors to β-actin of the tumor-injected mice were 
calculated by designating the ratio of untreated WT mice as 1.0 and shown with 
SEM (n = 6). A statistical analysis failed to detect significant differences between 
WT and CCR KO mice at each time point. (c) Immunohistochemical analysis of 
CCL2 proteins and CCR2-positive cells.  Immunohistochemical analysis was 
performed inside tumor foci (c-i to c-v) and in the sinusoids of tumor-free areas 
(c-vi) of liver tissues of WT mice 10 days (c-i, ii, iii, v and vi) and 14 days (c-iv) 
after tumor cell injection using rabbit anti-mouse CCL2 (c-i to c-iv) or goat 
anti-mouse CCR2 antibodies(c-v and c-vi). Representative results from at least 6 
individual animals in each group are shown. Original magnification, ×400 (c-i 
to c-v) and × 1000 (c-vi). Scale bars are 50 μm.  (d) The numbers of 
CCL2-positive cells inside tumor areas was enumerated and the cell density was 
determined on five randomly chosen tumor areas in WT (closed bars) and CCR2 
KO mice (open bars) at the indicated time intervals after tumor injection (n = 6). 
A statistical analysis failed to detect significant differences between WT and 
CCR KO mice at each time point. (e) Time course of CCL2 protein contents in 
liver homogenate after colon 26 injection.  All values and bars represent the 
mean and SEM calculated on the results from 6 individual animals, respectively.  
**, p<0.01. 
 
Figure 2 － Accumulation of macrophages inside tumor foci.  (a)  
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Immunohistochemical analysis using F4/80 antibody was performed on liver 
tissues obtained from WT (upper panels) and CCR2 KO mice (lower panels) at 
the indicated time intervals after tumor cell injection. Representative results from 
6 animals in each group are shown here. Original magnification, ×200. Scale 
bar, 50μm. Original magnification of the insets, ×400.  (b) The number of 
F4/80-positive cells was enumerated and the cell density was determined on five 
randomly chosen tumor areas in WT (closed bars) and CCR2 KO mice (open bars), 
or non-tumor areas in WT (dotted bars) and CCR2 KO mice (striped bars) at the 
indicated time intervals after tumor injection (n = 6). All values and bars 
represent the mean and SEM calculated on the results from 6 individual animals, 
respectively.  **, p<0.01. 
 
Figure 3 － Intratumoral αSMA-positive cell density.  (a to d).  
Immunohistochemical analysis using anti-αSMA mAb was performed on liver 
tissues obtained from WT mice (a and c) and CCR2 KO mice (b and d) at 10 days 
(a and b) and 14 days after the tumor injection (c and d) as described in Material 
and Methods. Representative results from 6 individual animals in each group are 
shown here. Original magnification, ×400. Scale bar, 50μm.  (e) The densities 
of intratumoral αSMA-positive areas in WT mice (closed bars) and CCR2 KO 
mice (open bars) were determined as described in Material and Methods. All 
values and bars represent the mean and SEM calculated on the results from 6 
individual animals, respectively. *, p<0.05. 
 
Figure 4 － Immunohistochemical detection of neovascularization inside 
metastasis foci.  (a to d) Immunostaining with anti-CD34 antibody was 
performed on liver obtained from WT mice (a and c) and CCR2 KO mice (b and 
d) at 10 days (a and b) and 14 days (c and d) after tumor cell injection. 
Representative results from 6 individual animals in each group are shown here. 
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Original magnification, ×400. Scale bar, 50μm.  (e) Intratumoral microvessel 
density (IMVD) in WT (closed bars) and CCR2 KO mice (open bars) were 
determined as described in Material and Methods. All values and bars represent 
the mean and SEM calculated on the results from 6 individual animals, 
respectively. *, p<0.05. 
 
Figure 5－Gene expression of angiogenic factors and MMPs.  (a) RT-PCR 
analysis was performed on total RNAs extracted from the livers of WT and CCR2 
KO mice at the indicated time intervals after the tumor injection as described in 
Material and Methods. RT-PCR analyses were performed, and representative 
results from 6 individual experiments are shown.  (b) The ratios of these factors 
to β-actin of the tumor-injected mice were calculated by designating the ratio of 
untreated WT mice as 1.0 and shown with SEM (n = 6). 
 
Figure 6 － Identification of MMP2-expressing cells by double-color 
immunofluorescence analyses.  Liver tissues of WT (a and upper panel of b) and 
CCR2 KO mice (b, lower panel) were obtained 14 days after tumor cell injection. 
Double-color immuofluorescence analyses were performed using the combination 
of anti-MMP2 and anti-F4/80 antibodies (a) or anti-MMP2 and anti-αSMA 
antibodies (b). Immunoreactive MMP2 were visualized individually in Cy3 (red), 
while either F4/80 or αSMA antigens were envisioned in FITC (green). Images 
were digitally merged.  Representative results from six individual animals are 
shown here. Original magnification, ×200 (a); ×400 (b, c). Scale bar, 50 μm. 
 
Figure 7－ Identification of CCR2-expressing cells.  Liver tissues of WT mice 
were obtained 14 days after tumor cell injection. (a, b) Double-color 
immuofluorescence analyses were performed using the combination of anti-CCR2 
and anti-F4/80 antibodies (a) or anti-CCR2 and anti-αSMA antibodies (b) 
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Immunoreactive CCR2 were visualized individually in i (Cy3, red) while either 
F4/80 or αSMA antigens were envisioned in ii (FITC, green). Images were 
digitally merged in iii.  Representative results from three individual animals are 
shown here. Original magnification, ×400. Scale bar, 50 μm. (c) RT-PCR 
analysis was performed for CCR2 gene expression in hepatic stellate cells 
isolated from untreated WT mice as described in Material and Methods. HSC, 
hepatic stellate cell; MNC, spleen mononuclear cells served as a positive control; 
No-RT, without reverse transcription, served as a negative control. 
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Table I－The sequences of the primers and the conditions used for RT-PCR 
analysis  





CCL2 AAGCCAGCTCTCTCTTCCTC CCTCTCTCTTGAGCTTGGTG 32 247 NM 011333
CCL7 CAAGAAACAAAAGATCCCCAAG GAATTCTGCAGCTAACACAATG 32 452 NM 013654








































































β-actin TGTGATGGTGGGAATGGGTCAG TTTGATGTCACGCACGATTTCC 25 514 NM 007393
 
Abbreviation used in Table I.  VEGF, vascular endothelial growth factor; bFGF, 
basic fibroblast growth factor; PlGF, placental growth factor; HGF, hepatocyte 
growth factor; flt-1, FMS-like tyrosine kinase 1/VEGF receptor 2; flk-1, fetal 
liver kinase, protein-tyrosine kinase receptor/VEGF receptor 1 

































































































Table II－Tumor formation in WT and CCR2 KO mice. WT and CCR2 KO mice 
were sacrificed at the indicated time intervals after tumor cell injection to 
determine the incidence of liver tumors, the liver weight, the liver to body weight 
ratio, the numbers of tumor foci in the liver, the foci number per cm2 and % tissue 
involved by tumor as described in Material and Methods. All the parameters were 
determined in mice, which developed liver tumor foci. Each value represents 
mean ± SEM. *, p<0.001; **, p<0.0001 compared between WT and CCR2 KO 
mice at the same time points. ND, not determined due to difficulties in 
macroscopical separation of individual tumors.  
1After the number of foci on day 14 were enumerated in ten randomly chosen 
H&E staining sections (×40 magnification) and the observed section areas were 
measured with the help of NIH Image software, the foci numbers per cm2 were 
calculated by dividing the foci numbers by the observed section areas. 
 







